For the listed ZYN pouches, FDA authorized a narrowly worded, modified-risk claim comparing them to cigarettes. FDA also built in postmarket monitoring and said it can withdraw the orders if it can no longer support the underlying public-health determinations.

What FDA authorized (the exact claim and which products)

FDA said the modified-risk claim may be used for these ZYN nicotine pouch products:

“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

FDA’s June 30 decision applies to two nicotine strengths (3 milligram and 6 milligram) for each of these flavors:

• ZYN Chill
• ZYN Cinnamon
• ZYN Citrus
• ZYN Coffee
• ZYN Cool Mint
• ZYN Menthol
• ZYN Peppermint
• ZYN Smooth
• ZYN Spearmint
• ZYN Wintergreen

FDA emphasized that this type of modified-risk order (an MRTP order) covers specific products, not an entire class of nicotine pouches.

What this does not mean for consumers

FDA says there is no safe tobacco product, and people who do not use tobacco products should not start. For adults who currently smoke cigarettes, FDA says the biggest health benefit comes from fully quitting all forms of tobacco.

At the same time, FDA describes the harm-reduction purpose of the MRTP pathway: for adults who smoke cigarettes, switching completely to FDA-authorized nicotine pouches “may reduce exposure” to many harmful chemicals found in cigarettes.

The key practical takeaway is that the modified-risk message is about relative risk compared with cigarettes and is tied to the specific ZYN products in FDA’s order—not a blanket approval for all nicotine pouches or all ZYN products.

How MRTP authorization works (and why it can be reversed)

FDA’s modified-risk orders are time-limited. FDA says the orders expire in five years, and before then the company may request and receive FDA authorization to continue marketing the products as MRTPs.

FDA also requires postmarket surveillance and studies, including an assessment of MRTP users’ behaviors and their understanding of the risk-related information. FDA says companies must submit the results to the agency annually, and FDA reviews the data for changes in use and health risks.

FDA also says it may withdraw the orders if it can no longer make the required determinations—for example, if there is a significant increase in youth uptake. Before FDA withdraws an MRTP order, FDA says it will provide an opportunity for an informal hearing.

What to watch next

Over the next five years, the most concrete “watch items” are the ones FDA built into the MRTP framework:

• Whether annual postmarket data continues to support the agency’s population-health determinations behind the claim.
• How FDA evaluates youth uptake and whether marketing restrictions are effectively limiting youth exposure.
• Whether FDA grants renewals as the fixed term approaches its end date.

In the near term, expect marketing and labeling for these 20 ZYN products to reflect FDA’s allowed modified-risk language—and expect the claim to be used only in the specific, product-tied way FDA authorized.

Sources

• FDA (CTP Newsroom): June 30, 2026 decision and exact modified-risk claim